|
Univariate
|
Multivariate
|
---|
HR
|
95% CI
|
p-Value
|
HR
|
95% CI
|
p-Value
|
---|
Local failure (LF)
|
HPVOPC
|
0.128
|
0.017-0.945
|
0.044*a
|
0.146
|
0.019-1.115
|
0.064
|
≥T3
|
1.580
|
0.731-3.413
|
0.244
|
-
|
-
|
-
|
ECE vs N+ b
|
2.849
|
1.014-8.007
|
0.047*a
|
2.262d
|
0.711-7.199
|
0.167
|
N+ vs N0 b
|
0.350
|
0.129-0.946
|
0.039*a
|
0.555d
|
0.173-1.779
|
0.322
|
pos. Marginsc
|
2.730
|
1.016-7.333
|
0.046*a
|
3.354
|
1.206-9.329
|
0.020*a
|
LVI
|
1.660
|
0.696-3.962
|
0.253
|
-
|
-
|
-
|
PNI
|
2.853
|
1.137-7.154
|
0.025*a
|
2.590
|
1.014-6.616
|
0.047*a
|
Rec. Tumor
|
1.730
|
0.519-5.761
|
0.372
|
-
|
-
|
-
|
Locoreginal failure (LRF)
|
HPVOPC
|
0.208
|
0.050-0.868
|
0.031*a
|
0.210
|
0.049-0.894
|
0.035*a
|
≥T3
|
1.470
|
0.742-2.912
|
0.270
|
-
|
-
|
-
|
ECE vs N+
|
2.855
|
1.167-6.985
|
0.022*a
|
2.939
|
1.155-7.473
|
0.024*a
|
N+ vs N0
|
0.398
|
0.165-0.960
|
0.040*a
|
0.468
|
0.167-1.312
|
0.149
|
pos. margins
|
1.610
|
0.781-3.317
|
0.197
|
-
|
-
|
-
|
LVI
|
2.063
|
0.984-4.323
|
0.055
|
2.214
|
0.967-5.067
|
0.060
|
PNI
|
1.844
|
0.779-4.363
|
0.164
|
-
|
-
|
-
|
Rec. Tumor
|
1.309
|
0.399-4.289
|
0.657
|
-
|
-
|
-
|
Distant failure (DF)
|
HPVOPC
|
0.267
|
0.082-0.870
|
0.028*a
|
0.153
|
0.036-0.644
|
0.010*a
|
≥T3
|
1.573
|
0.838-2.850
|
0.158
|
-
|
-
|
-
|
ECE vs N+
|
3.408
|
1.621-7.164
|
0.001*a
|
3.109
|
1.369-7.035
|
0.007*a
|
N+ vs N0
|
0.812
|
0.336-1.957
|
0.642
|
0.759
|
0.287-2.004
|
0.578
|
pos. margins
|
0.774
|
0.411-1.458
|
0.428
|
-
|
-
|
-
|
LVI
|
1.947
|
0.995-9.810
|
0.052
|
1.963
|
0.932-4.137
|
0.076
|
PNI
|
1.463
|
0.634-3.372
|
0.372
|
-
|
-
|
-
|
Rec. Tumor
|
0.319
|
0.044-2.324
|
0.259
|
-
|
-
|
-
|
Any failure (AF)
|
HPVOPC
|
0.232
|
0.084-0.643
|
0.005*a
|
0.161
|
0.050-0.523
|
0.002*a
|
≥T3
|
1.629
|
0.973-2.728
|
0.064
|
1.476d
|
0.822-2.648
|
0.192
|
ECE vs N+
|
3.126
|
1.668-5.858
|
<0.001*a
|
3.113
|
1.566-6.187
|
0.001*a
|
N+ vs N0
|
0.604
|
0.305-1.195
|
0.148*a
|
0.669
|
0.302-1.484
|
0.323
|
pos. margins
|
1.018
|
0.603-1.719
|
0.947
|
-
|
-
|
-
|
LVI
|
1.943
|
1.107-3.412
|
0.021*a
|
1.996
|
1.071-3.720
|
0.030*a
|
PNI
|
1.609
|
0.820-3.155
|
0.166
|
-
|
-
|
-
|
Rec. Tumor
|
0.949
|
0.344-2.622
|
0.920
|
-
|
-
|
-
|
Overall survival (OS)
|
HPVOPC
|
0.277
|
0.134-0.573
|
0.001*a
|
0.254
|
0.116-0.557
|
0.001*a
|
≥T3
|
1.385
|
0.926-2.072
|
0.113
|
-
|
-
|
-
|
ECE vs N+
|
1.684
|
1.065-2.663
|
0.027*a
|
1.393
|
0.834-2.327
|
0.205
|
N+ vs N0
|
1.127
|
0.675-1.883
|
0.647
|
1.984
|
1.091-3.610
|
0.025*a
|
pos. margins
|
0.745
|
0.497-1.116
|
0.154
|
-
|
-
|
-
|
LVI
|
1.284
|
0.799-2.064
|
0.302
|
-
|
-
|
-
|
PNI
|
1.666
|
0.995-2.790
|
0.052
|
1.462d
|
0.853-2.506
|
0.167
|
Rec. Tumor
|
0.816
|
0.357-1.864
|
0.630
|
-
|
-
|
-
|
Disease specific survival (DSS)
|
HPVOPC
|
0.076
|
0.010-0.557
|
0.011*a
|
0.079
|
0.011-0.576
|
0.012*a
|
≥T3
|
1.839
|
1.003-3.373
|
0.049*a
|
1.719
|
0.910-3.250
|
0.095
|
ECE vs N+
|
2.837
|
1.366-5.892
|
0.005*a
|
2.160
|
1.021-4.571
|
0.044*a
|
N+ s N0
|
0.668
|
0.300-1.486
|
0.322
|
1.093
|
0.484-2.463
|
0.831
|
pos. margins
|
0.522
|
0.220-1.239
|
0.140
|
-
|
-
|
-
|
LVI
|
1.628
|
0.832-3.187
|
0.155
|
-
|
-
|
-
|
PNI
|
1.791
|
0.842-3.812
|
0.130
|
-
|
-
|
-
|
Rec. Tumor
|
0.965
|
0.298-3.124
|
0.953
|
-
|
-
|
-
|
Disease free survival (DFS)
|
HPVOPC
|
0.300
|
0.156-0.575
|
<0.001*a
|
0.294
|
0.146-0.590
|
0.001*a
|
≥T3
|
1.463
|
1.005-2.130
|
0.047*a
|
1.369d
|
0.873-2.146
|
0.171
|
ECE vs N+
|
2.003
|
1.305-3.077
|
0.001*a
|
1.876
|
1.159-3.035
|
0.010*a
|
N+ vs N0
|
1.001
|
0.618-1.621
|
0.997
|
1.684
|
0.949-2.985
|
0.075
|
pos. margins
|
1.191
|
0.778-1.824
|
0.420
|
-
|
-
|
-
|
LVI
|
1.512
|
0.985-2.322
|
0.059
|
1.170d
|
0.718-1.906
|
0.528
|
PNI
|
1.604
|
0.984-2.613
|
0.058
|
1.236d
|
0.733-2.081
|
0.427
|
Rec. Tumor
|
0.854
|
0.397-1.836
|
0.685
|
-
|
-
|
-
|
- aP-values < 0.05 were marked with asterisk
- bNodal positive patients with ECE have been compared against nodal positive patients without ECE (ECE vs N+) and nodal positive patients without ECE against patients without nodal disease (N+ vs N0) to calculate the excess risk of ECE to nodal disease only
- cClose margin vs R0 was neither significant in univariate (HR = 2.200, p = 0.128), nor in multivariate (HR 1.113, p = 0.865) Factors eliminated during the backward-selection are shown for the sake of completeness in grey letters in multivariate analysis
- dFactors eliminated during the backward-selection are shown for the sake of completeness in multivariate analysis